Alemtuzumab in multiple sclerosis: Latest evidence and clinical prospects

Therapeutic Advances in Chronic Disease

Volumn 4, Issue 3, 2013, Pages 97-103

  Kousin Ezewu, Onajite ^a   Coles, Alasdair ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Alemtuzumab; Autoimmunity; Monoclonal antibodies; Multiple sclerosis

Indexed keywords

ALEMTUZUMAB; ANTIHISTAMINIC AGENT; BETA1A INTERFERON; GLATIRAMER; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PARACETAMOL; PLACEBO; RITUXIMAB; STEROID;

ANCA ASSOCIATED VASCULITIS; APLASTIC ANEMIA; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE THYROIDITIS; AUTOIMMUNITY; BEHCET DISEASE; BRAIN HEMORRHAGE; BURKITT LYMPHOMA; CYTOKINE RELEASE SYNDROME; DISEASE COURSE; DISEASE DURATION; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; EARLY INTERVENTION; EPSTEIN BARR VIRUS INFECTION; EXPANDED DISABILITY STATUS SCALE; FLU LIKE SYNDROME; GLOMERULONEPHRITIS; GRAVES DISEASE; HUMAN; HYPOTHYROIDISM; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LISTERIOSIS; LYMPHOCYTOPENIA; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE SCLEROSIS; NEUTROPENIA; NONHUMAN; OFF LABEL DRUG USE; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL DISABILITY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PURE RED CELL ANEMIA; PYOGENIC GRANULOMA; REVIEW; SIDE EFFECT; SPIROCHETE INFECTION; THYROID PAPILLARY CARCINOMA; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 84880440010     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622313479137     Document Type: Review

References (40)

1. Berker D. Isik S. Ozuguz U. Tutuncu Y. Kucukler K. Akbaba G. et al. (2011) Prevalence of incidental thyroid cancer and its ultrasonographic features in subcentimeter thyroid nodules of patients with hyperthyroidism. Endocrine 39: 13–20.
2. Broadley S. Deans J. Sawcer S. Clayton D. Compston D. (2000) Autoimmune disease in first-degree relatives of patients with multiple sclerosis: a UK survey. Brain 123: 1102–1111.
3. Clark R. Watanabe R. Teague J. Schlapbach C. Tawa M. Adams N. et al. (2012) Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. Sci Transl Med 4: 117ra7.
4. Clatworthy M. Wallin E. Jayne D. (2008) Anti-glomerular basement membrane disease after alemtuzumab. N Engl J Med 359: 768–769.
5. Cobbold S. Jayasuriya A. Nash A. Prospero T. Waldmann H. (1984) Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature 312: 548–551.
6. Cohen J. Coles A. Arnold D. Confavreux C. Fox E. Hartung H. et al. (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing–remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380: 1819–1828.
7. Coles A. Cox A. Le Page E. Jones J. Trip S. Deans J. et al. (2006) The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 253: 98–108.
8. Coles A. Fox E. Vladic A. Gazda S. Brinar V. Selmaj K. et al. (2011) Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol 10: 338–348.
9. Coles A. Fox E. Vladic A. Gazda S. Brinar V. Selmaj K. et al. (2012 a) Alemtuzumab more effective than interferon-1a at 5-year follow-up of camms 223 clinical trial. Neurology 78: 1069–1078.
10. Coles A. Twyman C. Arnold D. Cohen J. Confavreux C. Fox E. et al. (2012 b) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380: 1829–1839.
11. Coles A. Wing M. Molyneux P. Paolillo A. Davie C. Hale G. et al. (1999 a) Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 46: 296–304.
12. Coles A. Wing M. Smith S. Coraddu F. Greer S. Taylor C. et al. (1999 b) Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 354: 1691–1695.
13. Costelloe L. Jones J. Coles A. (2012) Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis. Expert Rev Neurother 12: 335–341.
14. Dyer M. Hale G. Hayhoe F. Waldmann H. (1989) Effects of campath-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 73: 1431–1439.
15. Fox E. Sullivan H. Gazda S. Mayer L. O'Donnell L. Melia K. et al. (2012) A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis. Eur J Neurol 19: 307–311.
16. Gilleece M. Dexter T. (1993) Effect of campath-1h antibody on human hematopoietic progenitors in vitro. Blood 82: 807–812.
17. Gilquin J. Viard J. Jubault V. Sert C. Kazatchkine M. (1998) Delayed occurrence of graves’ disease after immune restoration with HAART: highly active antiretroviral therapy. Lancet 352: 1907–1908.
18. Gomez-Almaguer D. Jaime-Perez J. Ruiz-Arguelles G. (2012) Antibodies in the treatment of aplastic anemia. Arch Immunol Ther Exp (Warsz) 60: 99–106.
19. Hale G. Bright S. Chumbley G. Hoang T. Metcalf D. Munro A. et al. (1983) Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood 62: 873–882.
20. Hill-Cawthorne G. Button T. Tuohy O. Jones J. May K. Somerfield J. et al. (2012) Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatr 83: 298–304.
21. Hirst C. Pace A. Pickersgill T. Jones R. McLean B. Zajicek J. et al. (2008) Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. J Neurol 255: 231–238.
22. Hsiao L. Liu J. Yen C. Wang W. Fan F. Chiou T. et al. (2001) Relapse of Graves’ disease after successful allogeneic bone marrow transplantation. Bone Marrow Transplant 28: 1151–1153.
23. Jones J. Phuah C. Cox A. Thompson S. Ban M. Shawcross J. et al. (2009) IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 119: 2052–2061.
24. Keating M. Flinn I. Jain V. Binet J. Hillmen P. Byrd J. et al. (2002) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99: 3554–3561.
25. Kim W. Han S. Kim T. Nam-Goong I. Gong G. Lee H. et al. (2004) Ultrasonographic screening for detection of thyroid cancer in patients with Graves’ disease’. Clin Endocrinol (Oxf) 60: 719–725.
26. King C. Ilic A. Koelsch K. Sarvetnick N. (2004) Homeostatic expansion of t cells during immune insufficiency generates autoimmunity. Cell 117: 265–277.
27. Kohler G. Milstein C. (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495–497.
28. Kraimps J. Bouin-Pineau M. Mathonnet M. de Calan L. Ronceray J. Visset J. et al. (2000) Multicentre study of thyroid nodules in patients with graves’ disease’. Br J Surg 87: 1111–1113.
29. Lockwood C. Hale G. Waldmann H. Jayne D. (2003) Remission induction in Bechet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH-1H. Rheumatology 42: 1539–1544.
30. Moreau T. Coles A. Wing M. Isaacs J. Hale G. Waldmann H. et al. (1996) Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 119: 225–237.
31. Moreau T. Thorpe J. Miller D. Moseley I. Hale G. Waldmann H. et al. (1994) Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 344: 298–301.
32. Prosperini L. Gallo V. Petsas N. Borriello G. Pozzilli C. (2009) One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis. Eur J Neurol 16: 1202–1209.
33. Rao S. Sancho J. Campos-Rivera J. Boutin P. Severy P. Weeden T. et al. (2012) Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. PloS ONE 7: e39416.
34. Riechmann L. Clark M. Waldmann H. Winter G. (1988) Reshaping human antibodies for therapy. Nature 332: 323–327.
35. Rudick R. Lee J. Simon J. Ransohoff R. Fisher E. (2004) Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 56: 548–555.
36. Rudick R. Polman C. (2009) Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol 8: 545–559.
37. Waldmann H. Hale G. (2005) Campath: from concept to clinic. Phil Trans R Soc Lond B Biol Sci 360: 1707–1711.
38. Waldmann H. Polliak A. Hale G. Or R. Cividalli G. Weiss L. et al. (1984) Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (Campath-1). Lancet 2: 483–486.
39. Weissenbacher A. Boesmueller C. Brandacher G. Oellinger R. Pratschke J. Schneeberger S. (2010) Alemtuzumab in solid organ transplantation and in composite tissue allotransplantation. Immunotherapy 2: 783–790.
40. Xia M. Tone M. Packman L. Hale G. Waldmann H. (1991) Characterization of the Campath-1 (CDW2) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone. Eur J Immunol 21: 1677–1684.